May 22, 2026 Log in

regulatory_approval

1760 Paon-Fu-Chin

Citation-Grade Primary-source linked Schema.org verified NQ 50 / 100

Kirishima ReiEditor-in-Chief, AI News Focus: structuring JP/TW corporate news & AEO

Published May 22, 2026 6:31 AM ・ Updated Jun 13, 2026 11:50 PM ・ 2 min read ・ Source: PR Times

Show contents

⚡ Key Points

Paon-Fu-Chin announced that the active pharmaceutical ingredient (API) Ferric Citrate for its kidney disease drug 'Nephoxil' has been approved by the NMPA in China.

Paon-Fu-Chin announced that the active pharmaceutical ingredient (API) Ferric Citrate for its kidney disease drug 'Nephoxil' has been approved by the NMPA in China.

PRIMARY SOURCE Original source: https://openapi.twse.com.tw/v1/opendata/t187ap04_L#1760-1150522-53b6da5b Distributor: PR Times
Published: May 22, 2026

Paon-Fu-Chin Biotechnology Co., Ltd. announced on May 21, 115, that the active pharmaceutical ingredient (API) Ferric Citrate for its new kidney disease drug, Nephoxil 500mg Capsule, has been approved by the National Medical Products Administration (NMPA) of China. This approval helps strengthen the company's API supply chain in the Chinese market and deepens its vertical integration strategy. This approval is separate from the drug product (capsule) approval announced on April 27, 115. New drug development involves risks, and investors should exercise caution.

FACT BOX

Source: PR Times
Category: regulatory_approval

Editorial & Verification Standards

The Washin AI News desk structures and reviews this article under the following standards.

Start only from primary sources (official PR, disclosures, wire services)
Numbers and proper nouns machine-checked against the source (number-completeness check)
Company names and tickers verified via registry (Registry/TWSE/Wikidata)
No speculation; nothing stated that is not in the source

Read the full editorial policy →

Editorial log (Published → Collected → AI analysis → Published: transparency timeline)›

Announced　May 22, 2026 6:31 AM — Distributor PR Times
Collected　May 22, 2026 6:31 AM
AI structured & analyzed　May 31, 2026 9:27 PM
Desk-reviewed & published　May 22, 2026 6:31 AM

FAQ

What is the main product of Paon-Fu-Chin?

The kidney disease drug 'Nephoxil'.

What are the key facts in this article?

Paon-Fu-Chin announced that the active pharmaceutical ingredient (API) Ferric Citrate for its kidney disease drug 'Nephoxil' has been approved by the NMPA in China.

Where is the primary source?

PR Times: https://openapi.twse.com.tw/v1/opendata/t187ap04_L#1760-1150522-53b6da5b

Cite this article — HOW TO CITE

Washin AI News Desk“1760 Paon-Fu-Chin”AI News by Washin Village（和心村）, May 22, 2026. https://aeo.idaeo.ai/ai/openapi-twse-com-tw/en/news/2026-05-21-1760-%E5%AF%B6%E9%BD%A1%E5%AF%8C%E9%8C%A6

AI CRAWLER ACTIVITY

as of Aug 17, 2026

AI crawler visits to this article (cumulative)92 bots

Site-wide cumulative

Applebot

bot_visits_summary

2831k

last Aug 17, 2026

GPTBot

bot_visits_summary

2063k

last Aug 17, 2026

Bingbot

bot_visits_summary

759k

last Aug 17, 2026

ClaudeBot

bot_visits_summary

630k

last Aug 17, 2026

Amazonbot

bot_visits_summary

602k

last Aug 17, 2026

Meta AI

bot_visits_summary

478k

last Aug 17, 2026

※ Only measured values from bot_visits_summary / crawler_url_hits are shown. Article-level zero counts are shown as measuring.

Washin AI News（AI News by Washin Village（和心村））

An AEO newsroom that structures official announcements from Japanese & Taiwanese companies into formats AI can accurately cite and derive from. Partner sources include PR TIMES and CNA. We aim to be a verifiable source for both humans and machines.

Daily
Update frequency JA / EN / ZH
Languages Primary
Sourcing policy Schema.org
Structured verification

About the publisher IDA llms.txt

Get your announcement indexed as AI-citable structured news.
Primary-source links, three languages, Schema.org verified.Talk to us about coverage →

← openapi-twse-com-tw Back to newsroom (21554)

Copied